MedTrace Logo

A Global Study of the PETAL Consortium

NCT06067347 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-04-09

No results posted yet for this study

Summary

The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.

Conditions

  • T-Cell and NK-Cell Neoplasm

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-05
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • United States
  • Australia
  • Japan
  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06067347 on ClinicalTrials.gov